Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF [PDF]
Antibiotics, 2021 Background: In order to establish the clinical breakpoint (CBP) of danofloxacin against G. parasuis, three cutoff values, including epidemiological cutoff value (ECV), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (COPD) and clinical cutoff value (
Zihui Xu +11 more
doaj +7 more sources
Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China [PDF]
Pathogens, 2021 Haemophilus parasuis can cause high morbidity and mortality in swine. Cefquinome possesses excellent antibacterial activity against pathogens causing diseases of the respiratory tract.
Kun Mi +7 more
doaj +7 more sources
Radiology and Oncology, 2023 t(14;18)(q32;q21) translocation is an important genetic feature of follicular lymphoma resulting in antiapoptotic B-cell lymphoma 2 (BCL2) protein overexpression. On chromosome 18 breakpoint-site variation is high but does not affect BCL2.
Panjan Matej +4 more
doaj +5 more sources
Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift [PDF]
Antibiotics, 2022 The study was to explore the rational use of danofloxacin against Mycoplasma gallisepticum (MG) based on its clinical breakpoint (CBP) and the effect on lung microbiota.
Shuge Wang +10 more
doaj +3 more sources
Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae [PDF]
Antibiotics, 2021 In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for Enterobacteriaceae from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis.
Ga Eun Park +8 more
doaj +4 more sources
Clinical Breakpoint of Apramycin to Swine Salmonella and Its Effect on Ileum Flora. [PDF]
Int J Mol Sci, 2022 The purpose of this study was to establish the clinical breakpoint (CBP) of apramycin (APR) against Salmonella in swine and evaluate its effect on intestinal microbiota. The CBP was established based on three cutoff values of wild-type cutoff value (COWT)
Dai X +6 more
europepmc +5 more sources
Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study [PDF]
Frontiers in Pharmacology, 2022 Clostridium perfringens causes significant morbidity and mortality in swine worldwide. Avilamycin showed no cross resistance and good activity for treatment of C. perfringens.
Anxiong Huang +21 more
doaj +2 more sources
Prudent Use of Tylosin for Treatment of Mycoplasma gallisepticum Based on Its Clinical Breakpoint and Lung Microbiota Shift [PDF]
Frontiers in Microbiology, 2021 The aim of this study was to explore the prudent use of tylosin for the treatment of chronic respiratory infectious diseases in chickens caused by Mycoplasma gallisepticum (MG) based on its clinical breakpoint (CBP) and its effect on lung microbiota. The
Anxiong Huang +19 more
doaj +2 more sources
Determination of Susceptibility Breakpoint for Cefquinome against Streptococcus suis in Pigs
Antibiotics, 2021 Streptococcus suis (S. suis), a zoonotic pathogen, causes severe diseases in both pigs and human beings. Cefquinome can display excellent antibacterial activity against gram-negative and gram-positive bacteria.
Kun Mi +9 more
doaj +2 more sources
Canadian Journal of Infectious Diseases and Medical Microbiology, 2014 In the absence of clinical resistance, breakpoints for many antimicrobial agents are often set high. Clinical failures following use of the agents over time requires re-evaluation of breakpoints.
Robert P Rennie, Ronald N Jones
doaj +2 more sources